all report title image
  • Published On : Oct 2022
  • Code : CMI205
  • Industry : Medical Devices
  • Pages : 140
  • Formats :

When atrial fibrillation occurs, the atria, the upper chambers of the heart that should beat in rhythm with the ventricles, instead beat irregularly and inconsistently. Many persons with A-fib may not experience any symptoms. However, A-fib may result in palpitations, a quick, pounding heartbeat, shortness of breath, or weakness. Atrial fibrillation episodes can be intermittent or recurrent. Even though A-fib is typically not a life-threatening condition, it is a significant medical issue that needs to be treated properly to avoid stroke. Medication, therapy to correct the heart rhythm, and catheter operations to obstruct incorrect heart signals are all possible forms of treatment for atrial fibrillation.

Global atrial fibrillation market is estimated to be valued at US$ 21,042.7 million in 2022 and is expected to exhibit a CAGR of 13.4% during the forecast period (2022-2030).

Figure 1. Global Atrial Fibrillation Market Share (%), by End User, 2022

Atrial Fibrillation  | Coherent Market Insights

Increasing prevalence of atrial fibrillation is expected to drive the growth of the global atrial fibrillation market over the forecast period.

Increasing prevalence of atrial fibrillation is expected to drive the growth of the global atrial fibrillation market over the forecast period. For instance, according to the data published on July 2022, on Centers for Disease Control and Prevention (CDC), stated that more than 454,000 hospitalizations with atrial fibrillation as the primary diagnosis happen each year in the United States.The condition contributes to about 158,000 deaths each year in U.S.

Figure 2. Global Atrial Fibrillation Market Share (%), by Region, 2022

Atrial Fibrillation  | Coherent Market Insights

Increasing approval of products is expected to drive the market growth over the forecast period.

Increasing approval of products is expected to drive the market growth over the forecast period. For instance, in August 2021, Abbott, which is a U.S.-based multinational medical devices and health care company announced that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer, Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage (LAA) – an area where blood clots can form in people suffering from AFib – reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.

Global Atrial Fibrillation Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs, medical devices and vaccines from one place to another.

CMI table icon

Atrial Fibrillation Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 21,042.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 13.4% 2030 Value Projection: US$ 57,729.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Procedure: Pharmacological (Anti-arrhythmic, Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery, Electric Cardioversion)
  • By Technology: Radiofrequency, Laser, Cryotherapy, Others
  • By End User: Hospitals, Speciality Clinics, Others
Companies covered:

AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.

Growth Drivers:
  • Increasing prevalence of atrial fibrillation
  • Increase in product launch
Restraints & Challenges:
  • Product recall

Global Atrial Fibrillation Market: Key Developments

IOn August 24, 2022, physIQ, which uses wearable biosensor data to generate personalized, clinically valid, actionable insights announced a strategic collaboration with InCarda Therapeutics, Inc., and a privately-held, clinical-stage biopharmaceutical company developed inhaled therapies for cardiovascular diseases. This collaboration will to accelerate Phase III Study in patients with atrial fibrillation.

On August 30, 2022, Medtronic plc, which is an U.S. medical device company technology, announced that it has completed the acquisition of Affera, Inc., which is medical technology company .This acquisition expands the Medtronic plc company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution.

Global Atrial Fibrillation Market: Restraint

The major factors that hinder growth of the global atrial fibrillation market include products recall. For instance, in February 2019, Medtronic Plc received U.S. Food and Drug Administration (FDA) product recall for implanted cardiac pacemakers, which affected 13,440 devices manufactured and distributed between March 2017 and January 2019.

Key Players

Major players operating in the global atrial fibrillation market include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.

Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. It is considered to be one of the most prevalent types of cardiac arrhythmia. When the heart beats too slowly, too quickly, or irregularly, it is called an arrhythmia. Atrial fibrillation if untreated, can lead to a stroke and other serious medical complications. Atrial fibrillation can be dangerous if a person have diabetes, high blood pressure or other diseases of the heart.

Atrial fibrillation may occur in isolated incidents or it may be a chronic illness, fluttering heartbeat, irregular pulse, weakness, dizziness, and fatigue. Atrial fibrillation is mostly brought on by chaotic signals that cause the atria, the two top chambers of your heart, to contract quickly and out of time. Because of how swiftly they contract, the heart's walls fibrillate. Atrial fibrillation may result from electrical system damage to your heart. The signals in the upper chambers of the heart are disorganized in atrial fibrillation. The outcome is a shaking of the higher chambers (quiver). The lower cardiac chambers are then attempted to be reached by the AV node, which is then inundated with impulses (ventricles). A quick and erratic heart rhythm results from this.

Market Dynamics

High consumption of alcohol is also expected to aid in growth of the market. For instance, according to data published on August 2021, on Gallup, Inc, which is an U.S. analytics and advisory company, stated that about 60% of U.S. adults drink alcoholic beverages in 2021.

Key features of the study:

  • This report provides an in-depth analysis of the global atrial fibrillation market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global atrial fibrillation market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global atrial fibrillation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global atrial fibrillation market

Detailed Segmentation:

  • Global Atrial Fibrillation Market, By Procedure:
    • Pharmacological
      • Anti-arrhythmic
      • Anti-coagulant
    • Non-Pharmacological
      • Catheter Ablation Procedures
      • Maze surgery
      • Electric Cardioversion
  • Global Atrial Fibrillation Market, By Technology:
    • Radiofrequency
    • Laser
    • Cryotherapy
    • Others
  • Global Atrial Fibrillation Market, By End User:
    • Hospitals
    • Speciality Clinics
    • Others
  • Global Atrial Fibrillation Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AtriCure, Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Biosense Webster, Inc
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Corporation
    • CardioFocus, Inc.
    • Endoscopic Technologies, Inc.
    • Sanofi Aventis
    • Johnson and Johnson Ltd
    • Abbott Laboratories

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global atrial fibrillation market size is estimated to be valued at US$ 21,042.7 million in 2022 and is expected to exhibit a CAGR of 13.4% between 2022 and 2030.
Factors such as increasing prevalence of atrial fibrillation and increase in product launch are expected to drive the market growth.
Hospitals is the leading end user segment in the market. 
The major factors hampering growth of the market include product recall.
Major players operating in the market include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo